The Lancet· Megan E Daly, Charles B Simone, Mary W Redman, Ming-Hui Hsieh, Paul J Hesketh, Chen Hu, Arta M Monjazeb, Conor E Steuer, Apar K Ganti, Rojano Kashani, Jessica R Bauman, Josephine L Feliciano, James Moon, Kimberly Ku, Nguyet Le-Lindqwister, Andrew M Baschnagel, Sanjay Maraboyina, Garrett B Sherwood, Daniel Almquist, Kristin A Higgins, Jhanelle E Gray, Jeffrey D Bradley, Karen Kelly·· 25 天前精选AI 评分66
SWOG/NRG S1914：阿替利珠单抗联合SBRT未改善高危早期NSCLC总生存
[Articles] Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial
AI 导读
SWOG/NRG S1914 III期随机对照试验显示，在高危、早期不可手术非小细胞肺癌（NSCLC）中，阿替利珠单抗联合立体定向体部放疗（SBRT）相比单纯放疗未改善总生存期，且联合组3级及以上不良事件报告更多。这是首个完整报告的评估免疫治疗用于不可手术早期NSCLC的III期合作组试验。
推荐理由
该III期随机试验公布了阿替利珠单抗联合SBRT在早期NSCLC中的OS与安全性结果，为免疫治疗早期介入提供阴性证据。
来源：The Lancet · thelancet.com